vs
Side-by-side financial comparison of SCYNEXIS INC (SCYX) and Zeo Energy Corp. (ZEO). Click either name above to swap in a different company.
SCYNEXIS INC is the larger business by last-quarter revenue ($18.6M vs $18.6M, roughly 1.0× Zeo Energy Corp.). SCYNEXIS INC runs the higher net margin — 65.7% vs -10.8%, a 76.5% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs -0.4%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs -4.0%).
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
SCYX vs ZEO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.6M | $18.6M |
| Net Profit | $12.3M | $-2.0M |
| Gross Margin | — | — |
| Operating Margin | 56.3% | -11.8% |
| Net Margin | 65.7% | -10.8% |
| Revenue YoY | 1808.5% | -0.4% |
| Net Profit YoY | 376.5% | -360.9% |
| EPS (diluted) | $0.25 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $18.6M | $18.6M | ||
| Q3 25 | $334.0K | $23.9M | ||
| Q2 25 | $1.4M | $18.1M | ||
| Q1 25 | $257.0K | $8.8M | ||
| Q4 24 | $977.0K | $18.6M | ||
| Q3 24 | $660.0K | $19.7M | ||
| Q2 24 | $736.0K | $14.8M | ||
| Q1 24 | $1.4M | $20.1M |
| Q4 25 | $12.3M | $-2.0M | ||
| Q3 25 | $-8.6M | $-3.2M | ||
| Q2 25 | $-6.9M | $-2.4M | ||
| Q1 25 | $-5.4M | $-6.4M | ||
| Q4 24 | — | $-435.3K | ||
| Q3 24 | $-2.8M | $-424.3K | ||
| Q2 24 | $-14.5M | $-277.8K | ||
| Q1 24 | $411.0K | $-1.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | 57.9% | ||
| Q2 25 | — | 59.8% | ||
| Q1 25 | — | 99.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 50.2% | ||
| Q2 24 | — | 52.3% | ||
| Q1 24 | — | — |
| Q4 25 | 56.3% | -11.8% | ||
| Q3 25 | -2516.5% | -8.3% | ||
| Q2 25 | -701.0% | -15.8% | ||
| Q1 25 | -3350.2% | -153.8% | ||
| Q4 24 | — | -6.0% | ||
| Q3 24 | -1563.6% | -15.2% | ||
| Q2 24 | -1255.0% | -18.0% | ||
| Q1 24 | -692.5% | -20.1% |
| Q4 25 | 65.7% | -10.8% | ||
| Q3 25 | -2572.2% | -13.5% | ||
| Q2 25 | -504.8% | -13.3% | ||
| Q1 25 | -2097.7% | -72.4% | ||
| Q4 24 | — | -2.3% | ||
| Q3 24 | -425.5% | -2.2% | ||
| Q2 24 | -1964.4% | -1.9% | ||
| Q1 24 | 29.9% | -7.6% |
| Q4 25 | $0.25 | — | ||
| Q3 25 | $-0.17 | — | ||
| Q2 25 | $-0.14 | — | ||
| Q1 25 | $-0.11 | $-0.48 | ||
| Q4 24 | — | $1.11 | ||
| Q3 24 | $-0.06 | $-0.08 | ||
| Q2 24 | $-0.30 | $0.03 | ||
| Q1 24 | $0.01 | $-1.54 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $40.0M | $6.1M |
| Total DebtLower is stronger | — | $79.1K |
| Stockholders' EquityBook value | $49.4M | $5.3M |
| Total Assets | $59.0M | $56.9M |
| Debt / EquityLower = less leverage | — | 0.01× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $40.0M | $6.1M | ||
| Q3 25 | $37.9M | $3.9M | ||
| Q2 25 | $44.8M | $68.7K | ||
| Q1 25 | $40.6M | $2.9M | ||
| Q4 24 | $59.3M | $5.6M | ||
| Q3 24 | $68.8M | $4.3M | ||
| Q2 24 | $73.0M | $5.3M | ||
| Q1 24 | $80.2M | — |
| Q4 25 | — | $79.1K | ||
| Q3 25 | — | $84.6K | ||
| Q2 25 | — | $642.8K | ||
| Q1 25 | — | $715.4K | ||
| Q4 24 | — | $787.7K | ||
| Q3 24 | — | $858.6K | ||
| Q2 24 | — | $1.6M | ||
| Q1 24 | — | $748.8K |
| Q4 25 | $49.4M | $5.3M | ||
| Q3 25 | $36.4M | $-1.7M | ||
| Q2 25 | $44.5M | $-59.4M | ||
| Q1 25 | $50.5M | $-23.1M | ||
| Q4 24 | $55.1M | $-88.9M | ||
| Q3 24 | $58.5M | $-39.3M | ||
| Q2 24 | $60.4M | $-53.0M | ||
| Q1 24 | $74.1M | $-173.0M |
| Q4 25 | $59.0M | $56.9M | ||
| Q3 25 | $51.1M | $58.5M | ||
| Q2 25 | $60.7M | $46.2M | ||
| Q1 25 | $67.9M | $47.4M | ||
| Q4 24 | $90.6M | $61.0M | ||
| Q3 24 | $99.0M | $47.1M | ||
| Q2 24 | $107.8M | $49.1M | ||
| Q1 24 | $118.3M | $50.1M |
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $18.4M | $2.4M |
| Free Cash FlowOCF − Capex | — | $2.3M |
| FCF MarginFCF / Revenue | — | 12.2% |
| Capex IntensityCapex / Revenue | — | 0.9% |
| Cash ConversionOCF / Net Profit | 1.50× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-9.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $18.4M | $2.4M | ||
| Q3 25 | $-8.7M | $-6.6M | ||
| Q2 25 | $-7.5M | $-2.3M | ||
| Q1 25 | $-7.5M | $-2.3M | ||
| Q4 24 | $-24.0M | $3.5M | ||
| Q3 24 | $765.0K | $162.2K | ||
| Q2 24 | $-10.9M | $-2.2M | ||
| Q1 24 | $-4.0M | $-10.2M |
| Q4 25 | — | $2.3M | ||
| Q3 25 | — | $-6.8M | ||
| Q2 25 | — | $-2.7M | ||
| Q1 25 | — | $-2.6M | ||
| Q4 24 | — | $3.4M | ||
| Q3 24 | — | $116.5K | ||
| Q2 24 | — | $-2.3M | ||
| Q1 24 | — | $-10.4M |
| Q4 25 | — | 12.2% | ||
| Q3 25 | — | -28.6% | ||
| Q2 25 | — | -15.0% | ||
| Q1 25 | — | -30.0% | ||
| Q4 24 | — | 18.2% | ||
| Q3 24 | — | 0.6% | ||
| Q2 24 | — | -15.6% | ||
| Q1 24 | — | -51.5% |
| Q4 25 | — | 0.9% | ||
| Q3 25 | — | 1.0% | ||
| Q2 25 | — | 2.4% | ||
| Q1 25 | — | 4.2% | ||
| Q4 24 | — | 0.5% | ||
| Q3 24 | — | 0.2% | ||
| Q2 24 | — | 0.7% | ||
| Q1 24 | — | 1.1% |
| Q4 25 | 1.50× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -9.75× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
ZEO
| Nonrelated Party | $18.1M | 98% |
| Related Party | $432.1K | 2% |
